Impact of biomarker development on drug safety assessment

Toxicology and Applied Pharmacology

Volumn 243, Issue 2, 2010, Pages 167-179

  Marrer, Estelle ^a   Dieterle, Frank ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Cardiotoxicity; Hepatoxicity; Nephrotoxicity; Personalized medicine; Safety biomarkers; Vascular injury

Indexed keywords

BIOLOGICAL MARKER; DRUG;

ANIMAL; CHEMICALLY INDUCED DISORDER; HEART DISEASE; HUMAN; KIDNEY DISEASE; METABOLISM; REVIEW; SAFETY; TOXIC HEPATITIS; VASCULAR DISEASE;

ANIMALS; BIOLOGICAL MARKERS; DRUG-INDUCED LIVER INJURY; HEART DISEASES; HUMANS; KIDNEY DISEASES; PHARMACEUTICAL PREPARATIONS; SAFETY; VASCULAR DISEASES;

EID: 77949410471     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2009.12.015     Document Type: Article

References (89)

1. Ascione, R., Lloyd, C.T., Underwood, M.J., Gomes, W.J., Angelini, G.D., On-pump versus off-pump coronary revascularization: evaluation of renal function. Ann. Thorac. Surg. 68:2 (1999), 493–498.
2. Bachorzewska-Gajewska, H., Malyszko, J., Sitniewska, E., Malyszko, J.S., Dobrzycki, S., Neutrophil-gelatinase-associated lipocalin and renal function after percutaneous coronary interventions. Am. J. Nephrol. 26:3 (2006), 287–292.
3. Bachorzewska-Gajewska, H., Malyszko, J., Sitniewska, E., Malyszko, J.S., Pawlak, K., Mysliwiec, M., Lawnicki, S., Szmitkowski, M., Dobrzycki, S., Could neutrophil-gelatinase-associated lipocalin and cystatin C predict the development of contrast-induced nephropathy after percutaneous coronary interventions in patients with stable angina and normal serum creatinine values?. Kidney Blood Press. Res. 30:6 (2007), 408–415.
4. Benoehr, P., Krueth, P., Bokemeyer, C., Grenz, A., Osswald, H., Hartmann, J.T., Nephroprotection by theophylline in patients with cisplatin chemotherapy: a randomized, single-blinded, placebo-controlled trial. J. Am. Soc. Nephrol. 16:2 (2005), 452–458.
5. Bertinchant, J.P., Robert, E., Polge, A., Marty-Double, C., Fabbro-Peray, P., Poirey, S., Aya, G., Juan, J.M., Ledermann, B., de la Coussaye, J.E., Dauzat, M., Comparison of the diagnostic value of cardiac troponin I and T determinations for detecting early myocardial damage and the relationship with histological findings after isoprenaline-induced cardiac injury in rats. Clin. Chim. Acta 298:1-2 (2000), 13–28.
6. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Therapeut. 69 (2001), 89–95.
7. Brott, D., Gould, S., Jones, H., Schofield, J., Prior, H., Valentin, J.P., Bjurstrom, S., Kenne, K., Schuppe-Koistinen, I., Katein, A., Foster-Brown, L., Betton, G., Richardson, R., Evans, G., Louden, C., Biomarkers of drug-induced vascular injury. Toxicol. Appl. Pharmacol. 207:2 Suppl (2005), 441–445.
8. Chesney, P.J., Davis, J.P., Purdy, W.K., Wand, P.J., Chesney, R.W., Clinical manifestations of toxic shock syndrome. JAMA 246:7 (1981), 741–748.
9. Clarke, H., Egan, D.A., Heffernan, M., Doyle, S., Byrne, C., Kilty, C., Ryan, M.P., Alpha-glutathione s-transferase (alpha-GST) release, an early indicator of carbon tetrachloride hepatotoxicity in the rat. Hum. Exp. Toxicol. 16:3 (1997), 154–157.
10. Coles, B.F., Kadlubar, F.F., Human alpha class glutathione S-transferases: genetic polymorphism, expression, and susceptibility to disease. Methods Enzymol. 401 (2005), 9–42.
11. Desikan, R., Veksler, Y., Raza, S., Stokes, B., Sabir, T., Li, Z.J., Jagannath, S., Nephrotic proteinuria associated with high-dose pamidronate in multiple myeloma. Br. J. Haematol. 119:2 (2002), 496–499.
12. Dharnidharka, V.R., Kwon, C., Stevens, G., Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am. J. Kidney Dis. 40:2 (2002), 221–226.
13. Diamond, J.R., Yoburn, D.C., Nonoliguric acute renal failure. Arch. Intern. Med. 142:10 (1982), 1882–1984.
14. EMEA Report, 2008. Doc. Ref. EMEA/679719/2008 Rev. 1. http://www.emea.europa.eu/pdfs/human/sciadvice/67971908en.pdf.
15. EMEA Scientific Advice Procedures Website. http://www.emea.europa.eu/htms/human/sciadvice/biomarkers.htm.
16. EMEA Biomarkers Website. http://wwww.emea.europa.eu/htms/human/mes/biomarkers.htm.
17. Emeigh Hart, S.G., Assessment of renal injury in vivo. J. Pharmacol. Toxicol. Methods 52:1 (2005), 30–45.
18. Ferré, N., Camps, J., Prats, E., Vilella, E., Paul, A., Figuera, L., Joven, J., Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage. Clin. Chem. 48:2 (2002), 261–268.
19. Furlong, C.E., Cole, T.B., Jarvik, G.P., Costa, L.G., Pharmacogenomic considerations of the paraoxonase polymorphisms. Pharmacogenomics, 2002, 341–348.
20. Gatanaga, H., Tachikawa, N., Kikuchi, Y., Teruya, K., Genka, I., Honda, M., Tanuma, J., Yazaki, H., Ueda, A., Kimura, S., Oka, S., Urinary beta2-microglobulin as a possible sensitive marker for renal injury caused by tenofovir disoproxil fumarate. AIDS Res. Hum. Retroviruses. 22:8 (2006), 744–748.
21. Giffen, P.S., Pick, C.R., Price, M.A., Williams, A., York, M.J., Alpha-glutathione S-transferase in the assessment of hepatotoxicity—its diagnostic utility in comparison with other recognized markers in the Wistar Han rat. Toxicol. Pathol. 30:3 (2002), 365–372.
22. Goldberg, D.M., Structural, functional, and clinical aspects of gamma-glutamyltransferase. Crit. Rev. Clin. Lab. Sci. 12:1 (1980), 1–58.
23. Goodsaid, F., Frueh, F., Process map proposal for the validation of genomic biomarkers. Pharmacogenomics 7 (2006), 773–782.
24. Guder, W.G., Hofmann, W., Markers for the diagnosis and monitoring of renal tubular lesions. Clin. Nephrol. 38:Suppl. 1 (1992), S3–S7.
25. Guo, X., Nzerue, C., How to prevent, recognize, and treat drug-induced nephrotoxicity. Cleve. Clin. J. Med. 69:4 (2002), 289–297.
26. Han, W.K., Bonventre, J.V., Biologic markers for early detection of acute kidney injury. Cur. Opin. Crit. Care 10 (2004), 476–482.
27. Han, W.K., Waikar, S.S., Johnson, A., Curhan, G.C., Devarajan, P., Bonventre, J.V., Urinary biomarkers for early detection of acute kidney injury. J. Am. Soc. Nephrol., 403A, 2006, 17.
28. Han, W.K., Waikar, S.S., Johnson, A., Betensky, R.A., Dent, C.L., Devarajan, P., Bonventre, J.V., Urinary biomarkers in the early diagnosis of acute kidney injury. Kidney Int. 73:7 (2008), 863–869.
29. Herget-Rosenthal, S., Marggraf, G., Hüsing, J., Göring, F., Pietruck, F., Janssen, O., Philipp, T., Kribben, A., Early detection of acute renal failure by serum cystatin C. Kidney Int. 66:3 (2004), 1115–1122.
30. Herget-Rosenthal, S., Poppen, D., Hüsing, J., Marggraf, G., Pietruck, F., Jakob, H.G., Philipp, T., Kribben, A., Prognostic value of tubular proteinuria and enzymuria in nonoliguric acute tubular necrosis. Clin. Chem. 50:3 (2004), 552–558.
31. Herget-Rosenthal, S., Pietruck, F., Volbracht, L., Philipp, T., Kribben, A., Serum cystatin C—a superior marker of rapidly reduced glomerular filtration after uninephrectomy in kidney donors compared to creatinine. Clin. Nephrol. 64:1 (2005), 41–46.
32. Higuchi, H., Sumita, S., Wada, H., Ura, T., Ikemoto, T., Nakai, T., Kanno, M., Satoh, T., Effects of sevoflurane and isoflurane on renal function and on possible markers of nephrotoxicity. Anesthesiology 89:2 (1998), 307–322.
33. Higuchi, H., Adachi, Y., Wada, H., Kanno, M., Satoh, T., Comparison of plasma alpha glutathione S-transferase concentrations during and after low-flow sevoflurane or isoflurane anaesthesia. Acta Anaesthesiol. Scand. 45:10 (2001), 1226–1229.
34. Hirsch, R., Dent, C., Pfriem, H., Allen, J., Beekman, R.H. III, Ma, Q., Dastrala, S., Bennett, M., Mitsnefes, M., Devarajan, P., NGAL is an early predictive biomarker of contrast-induced nephropathy in children. Pediatr. Nephrol. 22:12 (2007), 2089–2095.
35. Hunt, C.M., Papay, J.I., Edwards, R.I., Theodore, D., Alpers, D.H., Dollery, C., Debruin, T.W., Adkison, K.K., Stirnadel, H.A., Gibbs, T.G., Monitoring liver safety in drug development: the GSK experience. Regul. Toxicol. Pharmacol. 49:2 (2007), 90–100.
36. Ichimura, T., Hung, C.C., Yang, S.A., Stevens, J.L., Bonventre, J.V., Kidney injury molecule-1 : a tissue and urinary biomarker for nephrotoxicant-induced renal injury. A. J. Physiol. Rena.l Physiol. 286 (2004), F552–F563.
37. IMI SAFE-T Press Release, 2009. http://idw-online.de/pages/de/news333776.
38. Iqbal, M.P., Ali, A.A., Waqar, M.A., Mehboobali, N., Urinary N-acetyl-beta-D-glucosaminidase in rheumatoid arthritis. Exp. Mol. Med. 30:3 (1998), 165–169.
39. Jones, B.R., Bhalla, R.B., Mladek, J., Kaleya, R.N., Gralla, R.J., Alcock, N.W., Schwartz, M.K., Young, C.W., Reidenberg, M.M., Comparison of methods of evaluating nephrotoxicity of cis-platinum. Clin. Pharmacol. Ther. 27:4 (1980), 557–562.
40. Koerbin, G., Taylor, L., Dutton, J., Marshall, K., Low, P., Potter, J.M., Aminoglycoside interference with the Dade Behring pyrogallol red-molybdate method for the measurement of total urine protein. Clin. Chem. 47:12 (2001), 2183–2184.
41. Kola, I., Landis, J., Can the pharmaceutical industry reduce attrition rates?. Nature Rev. Drug Dev. 3 (2004), 711–715.
42. Latt, D., Weiss, J.B., Jayson, M.I., Beta 2-microglobulin levels in serum and urine of rheumatoid arthritis patients on gold therapy. Ann. Rheum. Dis. 40:2 (1981), 157–160.
43. Liangos, O, Han, W.K., Wald, R., Perianayagam, M.C., Mackinnon, R.W., Dolan, N., Warner, K.G., Symes, J.F., Bonventre, J.V., Jaber, B.L., Urinary kidney injury molecule-1 level is an early and sensitive marker of acute kidney injury following cardiopulmonary bypass. J. Am. Soc. Nephrol., 403A, 2006, 17.
44. Liangos, O., Perianayagam, M.C., Vaidya, V.S., Han, W.K., Wald, R., Tighiouart, H., MacKinnon, R.W., Li, L., Balakrishnan, V.S., Pereira, B.J., Bonventre, J.V., Jaber, B.L., Urinary N-acetyl-beta-(D)-glucosaminidase activity and kidney injury molecule-1 level are associated with adverse outcomes in acute renal failure. J. Am. Soc. Nephrol. 18:3 (2007), 904–912.
45. Loebstein, R., Koren, G., Ifosfamide-induced nephrotoxicity in children: critical review of predictive risk factors. Pediatrics, 101(6), 1998, E8.
46. Madero, M., Sarnak, M.J., Stevens, L.A., Serum cystatin C as a marker of glomerular filtration rate. Curr. Opin. Nephrol. Hypertens. 15:6 (2006), 610–616.
47. Marson, B., Critical Path” is on the road forward; FDA reports industry activity is high. The Pink Sheet, 69, 2007, 29.
48. Mattes, W.B., 2007. Experience with a biomarker consortium, Presentation. http://www.toxicology.org/isot/RC/ncac/symposia_files/Fall2007Mattes.pdf.
49. Maurer, G., 2005. Current experience with pre-clinical safety biomarker qualification, DIA Workshop 2005, Washington. http://www.fda.gov/cder/genomics/presentations_20051006/051007_13_Maurer.pdf.
50. Mishra, J., Dent, C., Tarabishi, R., Mitsnefes, M.M., Ma, Q., Kelly, C., Ruff, S.M., Zahedi, K., Shao, M., Bean, J., Mori, K., Barasch, J., Devarajan, P., Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 365:9466 (2008), 1231–1238.
51. Misra, M.K., Khanna, A.K., Sharma, R., Srinivasan, S., Serum malate dehydrogenase (MDH) in portal hypertension—its value as a diagnostic and prognostic indicator. Indian J. Med. Sci. 45:2 (1991), 31–34.
52. Mochida, S., Arai, M., Ohno, A., Yamanobe, F., Ishikawa, K., Matsui, A., Maruyama, I., Kato, H., Fujiwara, K., Deranged blood coagulation equilibrium as a factor of massive liver necrosis following endotoxin administration in partially hepatectomized rats. Hepatology 29:5 (1999), 1532–1540.
53. Mussap, M., Plebani, M., Biochemistry and clinical role of human cystatin C. Crit. Rev. Clin. Lab. Sci. 41:5-6 (2004), 467–550.
54. Newman, P.B., 2001. Daily life in the middle ages. McFarland and Co, Jefferson p 253.
55. Newsholme, S.J., Thudium, D.T., Gossett, K.A., Watson, E.S., Schwartz, L.W., Evaluation of plasma von Willebrand factor as a biomarker for acute arterial damage in rats. Toxicol. Pathol. 28:5 (2000), 688–693.
56. Ovens, J., Funding for accelerating drug development initiative critical. Nat. Rev. Drug Disc., 5, 2006, 271.
57. Ozer, J., Ratner, M., Shaw, M., Bailey, W., Schomaker, S., The current state of serum biomarkers of hepatotoxicity. Toxicology 245:3 (2008), 194–205.
58. Parikh, C.R., Jani, A., Mishra, J., Ma, Q., Kelly, C., Barasch, J., Edelstein, C.L., Devarajan, P., Urine NGAL and IL-18 are predictive biomarkers for delayed graft function following kidney transplantation. Am. J. Transplant. 6:7 (2006), 1639–1645.
59. Phillips, K.A., Van Bebber, S., Issa, A.M., Diagnostics and biomarker development: priming the pipeline. Nat. Rev. Drug Disc. 5 (2006), 463–469.
60. Polkinghorne, K.R., Detection and measurement of urinary protein. Curr. Opin. Nephrol. Hypertens. 15:6 (2006), 625–630.
61. Price, R.G., The role of NAG (N-acetyl-beta-D-glucosaminidase) in the diagnosis of kidney disease including the monitoring of nephrotoxicity. Clin. Nephrol. 38:Suppl 1 (1992), S14–S19.
62. PSTC Press Release, 2008. http://www.c-path.org/pdf/PSTC_nephro_VXDS_summary_final.pdf, June 13, 2008.
63. Rehman, S.U., Januzzi, J.L. Jr, Natriuretic peptide testing in clinical medicine. Cardiol. Rev. 16:5 (2008), 240–249.
64. Richmond, J.M., Sibbald, W.J., Linton, A.M., Linton, A.L., Patterns of urinary protein excretion in patients with sepsis. Nephron 31:3 (1982), 219–223.
65. Robert, S., Zarowitz, B.J, Is there a reliable index of glomerular filtration rate in critically ill patients. DICP Ann. Pharmacother 25 (1991), 169–178.
66. Rodrigo, L., Hernández, A.F., López-Caballero, J.J., Gil, F., Pla, A., Immunohistochemical evidence for the expression and induction of paraoxonase in rat liver, kidney, lung and brain tissue. Implications for its physiological role. Chem. Biol. Interact. 137:2 (2001), 123–137.
67. Schentag, J.J., Plaut, M.E., Patterns of urinary beta 2-microglobulin excretion by patients treated with aminoglycosides. Kidney Int. 17:5 (1980), 654–661.
68. Schetz, M., Dasta, J., Goldstein, S., Golper, T., Drug-induced acute kidney injury. Curr. Opin. Crit. Care 11 (2005), 555–565.
69. Schmid, H., Henger, A., Cohen, C.D., Frach, K., Gröne, H.J., Schlöndorff, D., Kretzler, M., Gene expression profiles of podocyte-associated molecules as diagnostic markers in acquired proteinuric diseases. J. Am. Soc. Nephrol. 14:11 (2003), 2958–2966.
70. Séronie-Vivien, S., Delanaye, P., Piéroni, L., Mariat, C., Froissart, M., Cristol, J.P., Cystatin C: current position and future prospects. Clin. Chem. Lab. Med. 46:12 (2008), 1664–1686.
71. Shlipak, M.G., Praught, M.L., Sarnak, M.J., Update on cystatin C: new insights into the importance of mild kidney dysfunction. Curr. Opin. Nephrol. Hypertens. 15:3 (2006), 270–275.
72. Skálová, S., The diagnostic role of urinary N-acetyl-beta-D-glucosaminidase (NAG) activity in the detection of renal tubular impairment. Acta Medica (Hradec Kralove) 48:2 (2005), 75–80.
73. Sundberg, A.G.M., Appelkvist, E.L., Bäckmann, L., Dallner, G., Urinary π-class glutathione transferase as an indicator of tubular damage in the human kidney. Nephron 67 (1994), 308–316.
74. Takuwa, S., Ito, Y., Ushijima, K., Uchida, K., Serum cystatin-C values in children by age and their fluctuation during dehydration. Pediatrics Int. 44 (2002), 28–31.
75. Temple, R., Hy's law: predicting serious hepatotoxicity. Pharmacoepidemiol. Drug Saf. 15:4 (2006), 241–243.
76. Thielemans, N., Lauwerys, R., Bernard, A., Competition between albumin and low-molecular-weight proteins for renal tubular uptake in experimental nephropathies. Nephron 66 (1994), 453–458.
77. Tirelli, A.S., Colombo, N., Cavanna, G., Mangioni, C., Assael, B.M., Follow-up study of enzymuria and beta 2 microglobulinuria during cis-platinum treatment. Eur. J. Clin. Pharmacol. 29:3 (1985), 313–318.
78. Tominaga, M., Fujiyama, K., Hoshino, T., Tanaka, Y., Takeuchi, T., Honda, M., Mokuda, O., Ikeda, T., Mashiba, H., Urinary N-acetyl-beta-D-glucosaminidase in the patients with hyperthyroidism. Horm. Metab. Res. 21:8 (1989), 438–440.
79. Tomlanovich, S., Golbetz, H., Perlroth, M., Stinson, E., Myers, DM, Limitations of creatinine in quantifying the severity of cyclosporine-induced chronic nephropathy. Am. J. Kidney Dis. 8:5 (1986), 332–337.
80. Trof, R.J., Di Maggio, F., Leemreis, J., Groeneveld, A.B.J., Biomarkers of acute renal injury and renal failure. Shock 26:3 (2006), 245–253.
81. US Department of Health and Human Services, Food and Drug Administration, 2004a. Innovation or stagnation: challenge and opportunity on the critical path to new medical products. http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html (2004).
82. US Department of Health and Human Services, Food and Drug Administration, 2004b. Guidance for industry: pharmacogenomic data submission. http://www.accessdata.fda.gov/cdrh_docs/reviews/K041627.pdf.
83. US Department of Health and Human Services, Food and Drug Administration, 2005. Drug-diagnostic co-development concept paper. http://www.fda.gov/cder/genomics/pharmacoconceptfn.pdf.
84. US Department of Health and Human Services, Food and Drug Administration, 2006. Critical Path Opportunities Report. http://www.fda.gov/oc/initiatives/criticalpath/reports/opp_report.pdf.
85. US Food and Drug Administration Agency, 2007. 510(k) Substantial equivalence determination decision summary device only, Rockville, USA. http://www.fda.gov/cdrh/reviews/K041878.pdf.
86. Westhuyzen, J., Endre, Z.H., Reece, G., Reith, D.M., Saltissi, D., Morgan, T.J., Measurement of tubular enzymuria facilitates early detection of acute renal impairment in the intensive care unit. Nephrol. Dial. Transplant. 18:3 (2003), 543–551.
87. Woodcock, J., 2008. Improving safety testing by qualification of new biomarkers, presentation. http://iccvam.niehs.nih.gov/meetings/10thAnnivSymp/Woodcock.pdf.
88. Xu, S., Venge, P., Lipocalins as biochemical markers of disease. Biochim. Biophys. Acta 1482 (2000), 298–307.
89. Zomas, A., Anagnostopoulos, N., Dimopoulos, M.A., Successful treatment of multiple myeloma relapsing after high-dose therapy and autologous transplantation with thalidomide as a single agent. Bone Marrow Transplant 25:12 (2000), 1319–1320.